Prevention of hypertension in patients with pre-hypertension: Protocol for the PREVER-prevention trial

Trials

Volumn 12, Issue , 2011, Pages

  Fuchs, Flávio D ^a   Fuchs, Sandra C ^a   Moreira, Leila B ^a   Gus, Miguel ^a   Nóbrega, Antônio C ^b   Poli de Figueiredo, Carlos E ^c   Mion, Décio ^d   Bortoloto, Luiz ^d   Consolim Colombo, Fernanda ^d   Nobre, Fernando ^d   Coelho, Eduardo B ^d   Vilela Martin, José F ^e   Moreno Jr, Heitor ^f   Cesarino, Evandro J ^d   Franco, Roberto ^g   Brandão, Andréa A ^h   de Sousa, Marcos R ⁱ   Ribeiro, Antônio L P ⁱ   Jardim, Paulo C ^j   Neto, Abrahão A ^k   Scala, Luiz C N ^l   Mota, Marco ^m   Chaves, Hilton ⁿ   Alves, João G ^o   Filho, Dario C S ^p   Pereira e Silva, Ricardo ^q   Neto, José A F ^r   Irigoyen, Maria C ^s   Castro, Iran ^s   Steffens, André A ^t   Schlatter, Rosane ^a   de Mello, Renato B ^a   Mosele, Francisca ^a   Ghizzoni, Flávia ^a   Berwanger, Otávio ^u   more..

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^h STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

ⁱ FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^j FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^k Anis Rassi Hospital   (Brazil)

^l HOSPITAL UNIVERSITÁRIO JÚLIO MÜLLER   (Brazil)

^m Faculdade de Medicina   (Brazil)

ⁿ FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^o INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^p FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^q FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^r Hospital Universitario   (Brazil)

^s INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^t FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^u Hospital do Coracao   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ALCOHOLIC BEVERAGE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CONTROL GROUP; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ETHICS; FRUIT; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOKALEMIA; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MICROALBUMINURIA; OBESITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREHYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SODIUM RESTRICTION; STROKE; SUDDEN DEATH; VASCULAR DISEASE; VEGETABLE; BLOOD PRESSURE; BRAZIL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PLACEBO EFFECT; TREATMENT OUTCOME;

ADULT; AGED; AMILORIDE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRAZIL; CHLORTHALIDONE; DIURETICS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLACEBO EFFECT; PREHYPERTENSION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 79952197520     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-65     Document Type: Article

References (26)

1. Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913. 10.1016/S0140-6736(02)11911-8, 12493255, Prospective Studies Collaboration.
2. World Health Report 2002 Reducing risks, promoting healthy life. 2002, Geneva, Switzerland: World Health Organization, Accessed October 27, 2010, World Health Report 2002., http://www.who.int/whr/2002
3. Sociedade Brasileira de Cardiologia/Sociedade Brasileira de Hipertensão/Sociedade Brasileira de Nefrologia. VI Brazilian Guidelines of Hypertension. Arq Bras Cardiol 2010, 95(1 supl 1):1-51.
4. Fuchs FD. Prehypertension: the rationale for early drug therapy. Cardiovasc Ther 2010, 28:339-43. 10.1111/j.1755-5922.2010.00167.x, 20553286.
5. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, LaCroix AZ, Black HR, . Women's Health Initiative Investigators Pre-hypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007, 115:855-60. 10.1161/CIRCULATIONAHA.106.656850, 17309936, Women's Health Initiative Investigators.
6. Russell LB, Valiyeva E, Carson JL. Effects of pre-hypertension on admissions and deaths: a simulation. Arch Intern Med 2004, 164:2119-24. 10.1001/archinte.164.19.2119, 15505125.
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665. 10.1136/bmj.b1665, 2684577, 19454737.
8. Guyton AC, Coleman TG, Cowley AV, Scheel KW, Manning RD, Norman RA. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972, 52:584-94. 10.1016/0002-9343(72)90050-2, 4337474.
9. Tobian L. Salt and hypertension. Lessons from animal models that relate to human hypertension. Hypertension 1991, 17(1 Suppl):I52-8.
10. Dahl LK. Salt intake and hypertension. Genest 1977, 548-559. Hypertension. New York, McGraw Hill, Koiw, Kuchel.
11. Folkow B, Hallback M, Lundgreen Y, Sivertsson R, Weiss L. Importance of adaptative changes in vascular design for establishment of primary hypertension, studied in man and in spontaneously hypertensive rats. Circ Res 1973, 32(Suppl I):2-16.
12. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-23.
13. Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A. High-normal blood pressure progression to hypertension in the Framingham Heart Study. Hypertension 1991, 17:22-27.
14. Moreira LB, Fuchs SC, Wiehe M, Gus M, Moraes RS, Fuchs FD. Incidence of hypertension in Porto Alegre, Brazil: a population-based study. J Hum Hypertens 2008, 22:48-50. 10.1038/sj.jhh.1002252, 17581600.
15. The Trials of Hypertension Prevention Collaborative Research Group Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 1997, 157:657-667. 10.1001/archinte.157.6.657, 9080920, The Trials of Hypertension Prevention Collaborative Research Group.
16. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997, 336:1117-1124. 10.1056/NEJM199704173361601, 9099655.
17. Premier Collaborative Research Group Effects of comprehensive lifestyle modification on blood pressure control. JAMA 2003, 289:2083-2093. 10.1001/jama.289.16.2083, 12709466, Premier Collaborative Research Group.
18. Hooper L, Bartlett C, Davey Smith G, Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ 2002, 325:628. 10.1136/bmj.325.7365.628, 126303, 12242173.
19. Fuchs FD, Gus M, Moreira WD, Moreira LB, Moraes RS, Rosito GA, et al. Blood pressure effects of antyhypertensive drugs and lifestyle modification in a Brazilian hypertensive cohort. J Hypert 1997, 15:783-792.
20. Julius S, Nesbitt S, Egan B, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006, 354:1685-97. 10.1056/NEJMoa060838, 16537662.
21. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League. Journal of Hypertension 2008, 26:1487-1496.
22. Fuchs FD. Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure. Expert Rev Cardiovasc Ther 2004, 2:771-5. 10.1586/14779072.2.5.771, 15350178.
23. Fuchs FD. The corporate bias and the molding of prescription practices: the case of hypertension. Braz J Med Biol Res 2009, 42:224-8.
24. Fuchs FD. Diuretics: still essential drugs for the management of hypertension. Expert Rev Cardiovasc Ther 2009, 7:591-8. 10.1586/erc.09.32, 19505274.
25. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000, 35:1025-30.
26. Guerrero P, Fuchs FD, Moreira LM, Martins VM, Bertoluci C, Fuchs SC, Gus M. Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide. Clin Exp Hypertens 2008, 30:553-64. 10.1080/10641960802441906, 18855259.